

WHY INVEST IN ARKG?

Exposure to Innovation: Aims for thematic multi-cap exposure to innovative elements including gene therapy bio-informatics, bio-inspired computing, molecular medicine, and pharmaceutical innovations.

Growth Potential: Aims to capture long-term growth with low correlation of relative returns to traditional growth strategies and negative correlation to value strategies.

Tool for Diversification: Offers a tool for diversification due to little overlap with traditional indices. It can be a complement to traditional value/growth strategies.

Grounded in Research: Combines top-down and bottom-up research in its portfolio management to identify innovative companies and convergence across markets.


Cost Effective: Provides a lower cost alternative to mutual funds with true active management in an Exchange Traded Fund (ETF) that invests in rapidly moving themes.

FUND DETAILS

As of December 31, 2025

Ticker	ARKG
Type	Active Equity ETF
CUSIP	00214Q302
ISIN	US00214Q3020
Primary Exchange	Cboe BZX
Inception Date	2014-10-31
Expense Ratio	0.75%
Fund AUM	\$1.16 Billion
Advisor	ARK Investment Management LLC
Fund Distributor	Foreside Fund Services, LLC
Number of Holdings	40-60
Weighted Avg. Market Cap	9 Billion
Median Market Cap	2 Billion
Active Share (S&P 500)	99%

GROWTH OF 10,000 USD SINCE INCEPTION



The line graph represents the cumulative performance of a hypothetical \$10,000 investment. The returns are net of the ETF's expenses but do not reflect the payment of any brokerage commissions or brokerage costs incurred as a result of buying or selling fund shares and do not reflect the deduction of taxes to which an investor would be subject as a result of owning or selling shares of the fund. If they did, the returns would be lower than those shown.

FUND PERFORMANCE

For periods ended December 31, 2025

	3 Months	YTD	1 Year	3 Years*	5 Years*	10 Years*	Since Inception*
• ARKG NAV	4.11%	22.73%	22.73%	0.84%	-20.77%	4.16%	4.09%
• ARKG Market Price	4.32%	23.07%	23.07%	0.87%	-20.75%	4.10%	4.10%
• NASDAQ Bitotech Index [XNBI]	17.11%	33.43%	33.43%	11.54%	4.52%	5.58%	6.25%
• S&P500 Index [SPX]	2.66%	17.88%	17.88%	23.01%	14.42%	14.82%	13.65%
• MSCI World Index [M1WO]	3.12%	21.09%	21.09%	21.17%	12.15%	12.17%	10.88%

Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal will fluctuate so that an investor's shares when redeemed may be worth more or less than the original cost. For the Fund's most recent month end performance, please visit www.ark-funds.com or call 1-800-679-7759. Returns for less than one year are not annualized. Net asset value ("NAV") returns are based on the dollar value of a single share of the ETF, calculated using the value of the underlying assets of the ETF minus its liabilities, divided by the number of shares outstanding. The NAV is typically calculated at 4:00 pm Eastern time on each business day the Cboe BZX Exchange is open for trading. Market returns are based on the trade price at which shares are bought and sold on the Cboe BZX Exchange, Inc. using the last share trade. Market performance does not represent the returns you would receive if you traded shares at other times. Total Return reflects reinvestment of distributions on ex-date for NAV returns and payment date for Market Price returns. The market price of the ETF's shares may differ significantly from their NAV during periods of market volatility.

FUND OBJECTIVE

ARKG is an actively managed ETF that seeks long-term growth of capital by investing under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including health care, information technology, materials, energy and consumer discretionary, that are relevant to the Fund's investment theme of the genomics revolution. Companies within ARKG are focused on extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business.

TOP TEN HOLDINGS

As of December 31, 2025

	SECURITY NAME	WEIGHT
1	CRISPR THERAPEUTICS AG	8.7%
2	TEMPUS AI INC	8.2%
3	GUARDANT HEALTH INC	5.9%
4	TWIST BIOSCIENCE CORP	5.9%
5	PERSONALIS INC	5.2%
6	BEAM THERAPEUTICS INC	5.2%
7	NATERA INC	4.7%
8	ILLUMINA INC	4.5%
9	10X GENOMICS INC	4.4%
10	RECURSION PHARMACEUTICALS INC	4.1%
		56.8%

Holdings are subject to change. For current portfolio holdings please download "Fund Holdings" as a CSV or PDF at ark-funds.com. Portfolio holdings should not be considered as investment advice or a recommendation to buy, sell or hold any particular security. It should not be assumed that an investment in the securities identified was or will be profitable.

TECHNOLOGY BREAKDOWN

Multiomic Technologies	46.4%
Precision Therapies	33.0%
Programmable Biology	8.4%
Neural Networks	7.8%
Next Gen Cloud	2.4%
Humanoid Robots	1.0%
Intelligent Devices	1.0%

MARKET CAPITALIZATION

Mega (\$100B+)	2.2%
Large (\$10 - \$100B)	28.0%
Medium (\$2 - \$10B)	32.0%
Small (\$300M - \$2B)	34.7%
Micro (\$50 - \$300M)	2.8%

SECTOR BREAKDOWN

Health Care	98.9%
Information Technology	0.9%

GEOGRAPHIC BREAKDOWN

North America	90.1%
Western Europe	9.9%

Holdings are subject to change. The Technology Breakdown is based on ARK's internal thematic research elements and portfolio company classification. Geographic Breakdown relates principally to the domicile of the issuers of the securities held in the ETF. Sector Breakdown is based on the Bloomberg Industry Classification System (BICS).

Before investing you should carefully consider the Fund's investment objectives, risks, charges and expenses. This and other information is in the prospectus, a copy of which may be obtained by visiting www.ark-funds.com. Please read the prospectus carefully before you invest.

The principal risks of investing in ARKG: **Equity Securities Risk.** The value of the equity securities the Fund holds may fall due to general market and economic conditions. **Foreign Securities Risk.** Investments in the securities of foreign issuers involve risks beyond those associated with investments in U.S. securities. **Health Care Sector Risk.** The health care sector may be adversely affected by government regulations and government health care programs, restrictions on government reimbursements for medical expenses, increases or decreases in the cost of medical products and services and product liability claims, among other factors. Many health care companies are heavily dependent on patent protection and intellectual property rights and the expiration of a patent may adversely affect their profitability. **Biotechnology Company Risk.** A biotechnology company's valuation can often be based largely on the potential or actual performance of a limited number of products and can accordingly be greatly affected if one of its products proves, among other things, unsafe, ineffective or unprofitable. Biotechnology companies are subject to regulation by, and the restrictions of, the U.S. Food and Drug Administration, the U.S. Environmental Protection Agency, state and local governments, and foreign regulatory authorities. **Pharmaceutical Company Risk.** Companies in the pharmaceutical industry can be significantly affected by, among other things, government approval of products and services, government regulation and reimbursement rates, product liability claims, patent expirations and protection and intense competition. Detailed information regarding the specific risks of ARKG can be found in the ETF's prospectus. Additional risks of investing in ARKG include Foreign Securities Risk, Information Technology Sector Risk, equity, market, management and non-diversification risks, as well as fluctuations in market value and NAV. An investment in an ETF is subject to risks and you can lose money on your investment in an ETF. There can be no assurance that the ETF will achieve its investment objective. The ETF's portfolio is more volatile than broad market averages. Shares of ARKG are bought and sold at market price (not NAV) and are not individually redeemed from the ETF. ETF shares may only be redeemed directly with the ETF at NAV by Authorized Participants, in very large creation units. There can be no guarantee that an active trading market for ETF shares will develop or be maintained, or that their listing will continue or remain unchanged. Buying or selling ETF shares on an exchange may require the payment of brokerage commissions and frequent trading may incur brokerage costs that detract significantly from investment returns.

The Adviser expects to invest at least 80% of the Fund's assets in Genomics Revolution Companies. However, certain of these companies do not currently derive a substantial portion of their current revenues from genomic-focused businesses and there is no assurance that any company will do so in the future, which may adversely affect the ability of the Fund to achieve its investment objective.

Index Descriptions: The S&P 500® Index is a widely recognized capitalization-weighted index that measures the performance of the large-capitalization sector of the U.S. stock market. **The MSCI World Index** represents large and mid-cap equity performance across 23 developed markets countries. Returns shown for the MSCI World Index are net of foreign withholding taxes applicable to U.S. investors. Securities in the ETF's portfolio will not match those in any index. **The NASDAQ Biotechnology Index** is designed to track the performance of a set of securities listed on The NASDAQ Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical companies, and is a modified market capitalization weighted index. The ETF is benchmark agnostic and corresponding portfolios may have significant non-correlation to any index. Index returns are generally provided as an overall market indicator. You cannot invest directly in an index. Although reinvestment of dividend and interest payments is assumed, no expenses are netted against an index's returns. Index performance information was furnished by sources deemed reliable and is believed to be accurate, however, no warranty or representation is made as to the accuracy thereof and the information is subject to correction.

Glossary: Active Share is a measure of the percentage of stock holdings in a manager's portfolio that differ from the benchmark index. **Value Strategy:** Traditional value investing is an investment strategy where stocks are selected that trade for less than their intrinsic values. **Growth Strategy:** Traditional growth investing is an investment strategy that focuses on stocks, whose earnings are expected to grow at an above-average rate compared to its industry or the overall market. **Correlation:** The degree to which two strategies move in relation to each other.

Foreside Fund Services LLC, distributor.

NOT FDIC INSURED - NO BANK GUARANTEE - MAY LOSE VALUE